UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

European heart journal, 2013-05, Vol.34 (17), p.1279-1291

2013

Volltextzugriff (PDF)

Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation

Clinical science (1979), 2022-03, Vol.136 (5), p.309-321

2022

Volltextzugriff (PDF)

Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment

Journal of lipids, 2021, Vol.2021, p.5585521-11

2021

Volltextzugriff (PDF)

Effect of niacin monotherapy on high density lipoprotein composition and function

Lipids in health and disease, 2020-08, Vol.19 (1), p.1-190, Article 190

2020

Volltextzugriff (PDF)

Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review

Journal of personalized medicine, 2024-09, Vol.14 (9), p.996

2024

Volltextzugriff (PDF)

FREQUENCY OF HYPERTRIGLYCERIDEMIA IN TYPE 2 DIABETIC PATIENTS RECEIVING STATIN THERAPY AND ITS CORRELATION WITH GLYCEMIC CONTROL

Journal of Postgraduate Medical Institute, 2020-12, Vol.34 (4), p.253

2020

Volltextzugriff (PDF)

The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

European heart journal. Cardiovascular pharmacotherapy, 2021-09, Vol.7 (5), p.453-459

2021

Volltextzugriff (PDF)

Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol

Current opinion in cardiology, 2013-07, Vol.28 (4), p.389-398

Wright, R Scott

2013

Volltextzugriff (PDF)

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

Platelets (Edinburgh), 2011-11, Vol.22 (7), p.495-503

2011

Volltextzugriff (PDF)

The role of niacin in lipid-lowering treatment: are we aiming too high?

Current pharmaceutical design, 2013, Vol.19 (17), p.3094-3106

2013

Volltextzugriff (PDF)

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients

Journal of the American Heart Association, 2015-09, Vol.4 (9), p.e001508-e001508

2015

Volltextzugriff (PDF)

Niacin: The Evidence, Clinical Use, and Future Directions

Current atherosclerosis reports, 2012-02, Vol.14 (1), p.49-59

2012

Volltextzugriff (PDF)

Non-obligatory role of prostaglandin D2 receptor subtype 1 in rosacea: Laropiprant in Comparison to a placebo did not alleviate the symptoms of erythematoelangiectaic rosacea

Journal of clinical pharmacology, 2015-02, Vol.55 (2), p.137-143

2015

Volltextzugriff (PDF)

Niacin–laropiprant fails to reduce the risk of vascular events

Nature reviews cardiology, 2014-10, Vol.11 (10), p.558-558

Huynh, Karina

2014

Volltextzugriff (PDF)

Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia

International journal of cardiology, 2013-07, Vol.167 (1), p.225-231

2013

Volltextzugriff (PDF)

Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome

Diabetes, obesity & metabolism, 2014-06, Vol.16 (6), p.545-552

2014

Volltextzugriff (PDF)

Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials

Journal of clinical lipidology, 2015-05, Vol.9 (3), p.313-325

2015

Volltextzugriff (PDF)

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D 2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

Journal of clinical pharmacology, 2010-11, Vol.50 (11), p.1273-1279

2010

Volltextzugriff (PDF)

Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia

Pharmacogenomics, 2015-08, Vol.16 (12), p.1387-1397

2015

Volltextzugriff (PDF)

Tredaptive (nicotinic acid/laropiprant) for the treatment of dyslipidaemia

Drugs in Context, 2012

Croom, Katherine

2012

Volltextzugriff (PDF)

Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels

Journal of thrombosis and thrombolysis, 2016-04, Vol.41 (3), p.433-435

2016

Volltextzugriff (PDF)

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia

Disease markers, 2015-01, Vol.2015 (2015), p.1-8

2015

Volltextzugriff (PDF)

Synthesis and biological evaluation of novel laropiprant derivatives as potential anti-allergic agents

Medicinal chemistry research, 2015-11, Vol.24 (11), p.3920-3931

2015

Volltextzugriff (PDF)

Nicotinic acid: clinical considerations

Expert opinion on drug safety, 2012-07, Vol.11 (4), p.551-564

2012

Volltextzugriff (PDF)

Niacin Laropiprant combination in the management of dyslipidemia: a novel pharmaceutical formulation

The Internet journal of cardiology, 2010, Vol.8 (2)

2010

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(78)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Laropiprant
(68)
Life Sciences & Biomedicine
(59)
Science & Technology
(59)
Humans
(55)
Niacin
(36)
Female
(34)
Male
(34)
Middle Aged
(31)
Adult
(26)
Dyslipidemias - Drug Therapy
(26)
Niacin - Adverse Effects
(26)
Pharmacology & Pharmacy
(25)
Aged
(24)
Cardiovascular System & Cardiology
(23)
Indoles - Adverse Effects
(22)
Niacin - Administration & Dosage
(22)
Indoles - Administration & Dosage
(21)
Hypolipidemic Agents - Therapeutic Use
(20)
Double-Blind Method
(19)
Hypolipidemic Agents - Adverse Effects
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation

Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment

Effect of niacin monotherapy on high density lipoprotein composition and function

Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review

FREQUENCY OF HYPERTRIGLYCERIDEMIA IN TYPE 2 DIABETIC PATIENTS RECEIVING STATIN THERAPY AND ITS CORRELATION WITH GLYCEMIC CONTROL

The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

The role of niacin in lipid-lowering treatment: are we aiming too high?

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients

Niacin: The Evidence, Clinical Use, and Future Directions

Non-obligatory role of prostaglandin D2 receptor subtype 1 in rosacea: Laropiprant in Comparison to a placebo did not alleviate the symptoms of erythematoelangiectaic rosacea

Niacin–laropiprant fails to reduce the risk of vascular events

Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia

Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome

Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D 2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia

Tredaptive (nicotinic acid/laropiprant) for the treatment of dyslipidaemia

Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia

Synthesis and biological evaluation of novel laropiprant derivatives as potential anti-allergic agents

Nicotinic acid: clinical considerations

Niacin Laropiprant combination in the management of dyslipidemia: a novel pharmaceutical formulation

Suchergebnisse filtern